Evercore ISI lowered the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $41 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a “notable lengthening” of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics announces inducement grant under Nasdaq listing rule
- Viridian Therapeutics Stockholders Approve Key Proposals
- Viridian Therapeutics’ Veligrotug Shows Promising Durability and Safety in TED Treatment, Justifying Buy Rating
- Viridian Therapeutics: Promising Developments in Thyroid Eye Disease Treatment Drive Buy Rating
- Positive Outlook for Viridian Therapeutics: Buy Rating Affirmed on Promising Trial Results and Future Prospects